DermResearch, Inc. — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$17,334	106
2024	Research	$128,576	152
2023	Research	$120,164	112
2022	Research	$52,897	6
2021	Research	$34,378	10
2020	Research	$12,426	5
2019	Research	$26,650	4

Breakdown

Who paid Research payments · program years 2019–2025

Incyte Corporation $249,075 381 payments
Merck Sharp & Dohme Corporation $116,701 10 payments
Taro Pharmaceuticals USA, Inc. $26,650 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $109,071 8 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis $92,693 132 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis $75,222 109 payments
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream $31,031 19 payments
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $27,999 12 payments
CTBC 1705 $26,650 4 payments
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma $12,426 5 payments
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $7,590 1 payment
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream $5,232 84 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis $4,473 20 payments

What the money was spent on Research payments · program years 2019–2025

Professional salary support $23,450 3 payments
Overhead $3,200 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.